<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-81 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-81</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-81</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-7.html">extraction-schema-7</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD-1 therapy duration strategies and outcomes in melanoma, including planned/actual duration, stopping rules, and whether optimal duration differs by depth of response (CR/PR/SD). Capture setting (metastatic vs adjuvant), regimen, response-stratified relapse and survival after stopping, comparisons of stopping vs continuing, biomarkers guiding discontinuation (e.g., PET/ctDNA), retreatment outcomes after relapse, toxicity with prolonged therapy, and any cost-effectiveness or modeling analyses. Prefer concise, numeric, and timepoint-specific results where available.</div>
                <p><strong>Paper ID:</strong> paper-db223548c10a908e465164b45c3b293a5a6ecf88</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/db223548c10a908e465164b45c3b293a5a6ecf88" target="_blank">Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy</a></p>
                <p><strong>Paper Venue:</strong> Frontiers in Oncology</p>
                <p><strong>Paper TL;DR:</strong> An overview of the main immune-oncology treatment strategies that, either alone or in combination, are undergoing clinical development are provided, including adoptive transfer of ex vivo activated T cells, immunomodulatory monoclonal antibodies, and cancer vaccines.</p>
                <p><strong>Paper Abstract:</strong> After Coley’s observation in 1891 of tumor regression in a patient who developed a postoperative infection, the field of immunotherapy is finally reborn. Avoiding immune destruction is now considered a hallmark of cancer, and the immunotherapy arena has exploded with the recent advances demonstrating an improvement in survival and a durability of response in patients with different cancer types, which translates into improved overall survival benefit. Here, we provide an overview of the main immune-oncology treatment strategies that, either alone or in combination, are undergoing clinical development. Namely, we will refer to those immunotherapeutic strategies that include adoptive transfer of ex vivo activated T cells, immunomodulatory monoclonal antibodies, and cancer vaccines. Our major focus will be to describe these approaches in melanoma, a cancer type transformed by immunotherapy into a potentially curable disease.</p>
                <p><strong>Cost:</strong> 0.019</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e81.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e81.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD-1 therapy duration strategies and outcomes in melanoma, including planned/actual duration, stopping rules, and whether optimal duration differs by depth of response (CR/PR/SD). Capture setting (metastatic vs adjuvant), regimen, response-stratified relapse and survival after stopping, comparisons of stopping vs continuing, biomarkers guiding discontinuation (e.g., PET/ctDNA), retreatment outcomes after relapse, toxicity with prolonged therapy, and any cost-effectiveness or modeling analyses. Prefer concise, numeric, and timepoint-specific results where available.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Pembrolizumab (early-phase, Hamid 2013)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Pembrolizumab (lambrolizumab) early-phase study in melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase I report of anti-PD-1 (lambrolizumab/pembrolizumab) showing high rates of sustained tumor regression in 135 melanoma patients with mainly grade 1–2 toxicities; cited as early evidence of durable responses.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_identifier</strong></td>
                            <td>Hamid et al. 2013 (lambrolizumab phase I)</td>
                        </tr>
                        <tr>
                            <td><strong>paper_title</strong></td>
                            <td>Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2013</td>
                        </tr>
                        <tr>
                            <td><strong>doi_or_trial_id</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>phase I / early-phase clinical trial (reported)</td>
                        </tr>
                        <tr>
                            <td><strong>setting</strong></td>
                            <td>metastatic/unresectable (mixed prior ipilimumab status reported)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>n=135 (reported in review)</td>
                        </tr>
                        <tr>
                            <td><strong>therapy_regimen</strong></td>
                            <td>Anti-PD-1 monotherapy (lambrolizumab/pembrolizumab) — dosing not specified in this review</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_monotherapy</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>duration_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>stopping_criteria</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>median_time_on_therapy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_at_discontinuation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_response_stratified_outcomes</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_by_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>compare_stop_vs_continue</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_rate_after_stop</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>re_treatment_outcomes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_vs_duration</strong></td>
                            <td>Reported mainly grade 1–2 toxic effects; review gives no data linking toxicity incidence to longer duration of therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_guiding_stop</strong></td>
                            <td>No biomarker-driven stopping strategy reported; review discusses PD-L1 as a potential predictor of response but not as a discontinuation guide.</td>
                        </tr>
                        <tr>
                            <td><strong>cost_effectiveness</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_after_stop</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>authors_recommendation</strong></td>
                            <td>No explicit recommendation on optimal duration or response-adapted stopping in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>key_limitations</strong></td>
                            <td>Early-phase data cited; review does not report planned/actual duration, stopping rules, or response-stratified relapse after stopping.</td>
                        </tr>
                        <tr>
                            <td><strong>country_or_registry</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>notes</strong></td>
                            <td>Cited to support durability of responses with anti-PD-1 but no details on treatment duration or stopping.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy', 'publication_date_yy_mm': '2015-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e81.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e81.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD-1 therapy duration strategies and outcomes in melanoma, including planned/actual duration, stopping rules, and whether optimal duration differs by depth of response (CR/PR/SD). Capture setting (metastatic vs adjuvant), regimen, response-stratified relapse and survival after stopping, comparisons of stopping vs continuing, biomarkers guiding discontinuation (e.g., PET/ctDNA), retreatment outcomes after relapse, toxicity with prolonged therapy, and any cost-effectiveness or modeling analyses. Prefer concise, numeric, and timepoint-specific results where available.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KEYNOTE-002</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KEYNOTE-002: randomized comparison pembrolizumab vs chemotherapy in ipilimumab-refractory melanoma (phase II)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase II randomized trial (reported in review) showing pembrolizumab improved PFS versus chemotherapy in ipilimumab-refractory advanced melanoma; 6-month PFS >30% with pembrolizumab vs 16% with chemotherapy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_identifier</strong></td>
                            <td>KEYNOTE-002</td>
                        </tr>
                        <tr>
                            <td><strong>paper_title</strong></td>
                            <td>A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2015</td>
                        </tr>
                        <tr>
                            <td><strong>doi_or_trial_id</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>randomized controlled phase II</td>
                        </tr>
                        <tr>
                            <td><strong>setting</strong></td>
                            <td>metastatic/unresectable, ipilimumab-refractory</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>n=540 (reported in review)</td>
                        </tr>
                        <tr>
                            <td><strong>therapy_regimen</strong></td>
                            <td>Pembrolizumab (monotherapy) versus chemotherapy; dosing/schedule not specified in review</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_monotherapy</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>duration_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>stopping_criteria</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>median_time_on_therapy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_at_discontinuation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_response_stratified_outcomes</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_by_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>compare_stop_vs_continue</strong></td>
                            <td>Trial compares pembrolizumab vs chemotherapy for PFS; not a stopping-duration comparison. Reported 6-month PFS: pembrolizumab >30% vs chemotherapy 16%.</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_rate_after_stop</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>re_treatment_outcomes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_vs_duration</strong></td>
                            <td>Review notes pembrolizumab had less high-grade toxicity than ipilimumab in other comparisons; no duration-toxicity relationship reported.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_guiding_stop</strong></td>
                            <td>No discontinuation biomarker used/reported in review for this trial; PD-L1 discussed elsewhere as predictive of response but not for stopping.</td>
                        </tr>
                        <tr>
                            <td><strong>cost_effectiveness</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_after_stop</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>authors_recommendation</strong></td>
                            <td>No recommendation on treatment duration or response-adapted stopping provided in review.</td>
                        </tr>
                        <tr>
                            <td><strong>key_limitations</strong></td>
                            <td>Review reports efficacy at 6 months but provides no information on planned treatment duration, stopping rules, or outcomes after elective discontinuation.</td>
                        </tr>
                        <tr>
                            <td><strong>country_or_registry</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>notes</strong></td>
                            <td>Numeric result reported: 6-month PFS >30% for pembrolizumab vs 16% for chemotherapy (as stated in review).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy', 'publication_date_yy_mm': '2015-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e81.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e81.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD-1 therapy duration strategies and outcomes in melanoma, including planned/actual duration, stopping rules, and whether optimal duration differs by depth of response (CR/PR/SD). Capture setting (metastatic vs adjuvant), regimen, response-stratified relapse and survival after stopping, comparisons of stopping vs continuing, biomarkers guiding discontinuation (e.g., PET/ctDNA), retreatment outcomes after relapse, toxicity with prolonged therapy, and any cost-effectiveness or modeling analyses. Prefer concise, numeric, and timepoint-specific results where available.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Pembrolizumab vs Ipilimumab (Robert 2015)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Randomized trial of pembrolizumab versus ipilimumab in advanced melanoma (NEJM 2015)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Large randomized study reported in the review (n=834) showing pembrolizumab prolonged PFS and OS versus ipilimumab and had less high-grade toxicity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Pembrolizumab versus ipilimumab in advanced melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_identifier</strong></td>
                            <td>Robert et al. 2015 (pembrolizumab vs ipilimumab)</td>
                        </tr>
                        <tr>
                            <td><strong>paper_title</strong></td>
                            <td>Pembrolizumab versus ipilimumab in advanced melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2015</td>
                        </tr>
                        <tr>
                            <td><strong>doi_or_trial_id</strong></td>
                            <td>10.1056/NEJMoa1503093</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>randomized phase III</td>
                        </tr>
                        <tr>
                            <td><strong>setting</strong></td>
                            <td>metastatic/unresectable, previously untreated and/or mixed settings as per trial (reported aggregated)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>n=834 (reported in review)</td>
                        </tr>
                        <tr>
                            <td><strong>therapy_regimen</strong></td>
                            <td>Pembrolizumab monotherapy versus ipilimumab monotherapy; dosing not specified in review</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_monotherapy</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>duration_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>stopping_criteria</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>median_time_on_therapy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_at_discontinuation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_response_stratified_outcomes</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_by_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>compare_stop_vs_continue</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_rate_after_stop</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>re_treatment_outcomes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_vs_duration</strong></td>
                            <td>Pembrolizumab had less high-grade toxicity than ipilimumab (trial-level comparison); no data linking toxicity to cumulative duration in review.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_guiding_stop</strong></td>
                            <td>PD-L1 expression discussed as potential predictor of response elsewhere in the review; not used as stopping rule in this trial per review text.</td>
                        </tr>
                        <tr>
                            <td><strong>cost_effectiveness</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_after_stop</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>authors_recommendation</strong></td>
                            <td>No specific recommendation on duration or response-stratified stopping is provided in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>key_limitations</strong></td>
                            <td>Review cites efficacy and toxicity comparisons but does not report any planned duration or stopping rules nor outcomes after elective discontinuation.</td>
                        </tr>
                        <tr>
                            <td><strong>country_or_registry</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>notes</strong></td>
                            <td>Study cited to demonstrate superiority of pembrolizumab over ipilimumab for PFS/OS and safety; no discontinuation strategy data.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy', 'publication_date_yy_mm': '2015-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e81.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e81.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD-1 therapy duration strategies and outcomes in melanoma, including planned/actual duration, stopping rules, and whether optimal duration differs by depth of response (CR/PR/SD). Capture setting (metastatic vs adjuvant), regimen, response-stratified relapse and survival after stopping, comparisons of stopping vs continuing, biomarkers guiding discontinuation (e.g., PET/ctDNA), retreatment outcomes after relapse, toxicity with prolonged therapy, and any cost-effectiveness or modeling analyses. Prefer concise, numeric, and timepoint-specific results where available.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Nivolumab vs Dacarbazine (Robert 2015)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Nivolumab in previously untreated melanoma without BRAF mutation (NEJM 2015)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase III trial reported in the review (n=418) showing improved 1-year overall survival with nivolumab versus dacarbazine (72.9% vs 42.1%).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Nivolumab in previously untreated melanoma without BRAF mutation.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_identifier</strong></td>
                            <td>Robert et al. 2015 (nivolumab vs dacarbazine)</td>
                        </tr>
                        <tr>
                            <td><strong>paper_title</strong></td>
                            <td>Nivolumab in previously untreated melanoma without BRAF mutation.</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2015</td>
                        </tr>
                        <tr>
                            <td><strong>doi_or_trial_id</strong></td>
                            <td>10.1056/NEJMoa1412082</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>randomized phase III</td>
                        </tr>
                        <tr>
                            <td><strong>setting</strong></td>
                            <td>metastatic/unresectable, previously untreated, BRAF wild-type</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>n=418 (reported in review)</td>
                        </tr>
                        <tr>
                            <td><strong>therapy_regimen</strong></td>
                            <td>Nivolumab monotherapy versus dacarbazine chemotherapy; dosing not specified in review</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_monotherapy</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>duration_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>stopping_criteria</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>median_time_on_therapy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_at_discontinuation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_response_stratified_outcomes</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_by_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>compare_stop_vs_continue</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_rate_after_stop</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>re_treatment_outcomes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_vs_duration</strong></td>
                            <td>Nivolumab led to fewer toxic effects than dacarbazine (trial-level safety); no data on toxicity as a function of treatment duration in review.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_guiding_stop</strong></td>
                            <td>Review notes PD-L1 expression may correlate with response but gives no role for it in guiding discontinuation.</td>
                        </tr>
                        <tr>
                            <td><strong>cost_effectiveness</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_after_stop</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>authors_recommendation</strong></td>
                            <td>No comment in review about optimal treatment duration or whether duration should differ by depth of response.</td>
                        </tr>
                        <tr>
                            <td><strong>key_limitations</strong></td>
                            <td>Trial-level efficacy/survival reported; review does not provide information on stopping rules, elective discontinuation, or outcomes after stopping.</td>
                        </tr>
                        <tr>
                            <td><strong>country_or_registry</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>notes</strong></td>
                            <td>Numeric: 1-year OS 72.9% (nivolumab) vs 42.1% (dacarbazine) as reported in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy', 'publication_date_yy_mm': '2015-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e81.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e81.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD-1 therapy duration strategies and outcomes in melanoma, including planned/actual duration, stopping rules, and whether optimal duration differs by depth of response (CR/PR/SD). Capture setting (metastatic vs adjuvant), regimen, response-stratified relapse and survival after stopping, comparisons of stopping vs continuing, biomarkers guiding discontinuation (e.g., PET/ctDNA), retreatment outcomes after relapse, toxicity with prolonged therapy, and any cost-effectiveness or modeling analyses. Prefer concise, numeric, and timepoint-specific results where available.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Nivolumab + Ipilimumab combination</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Combination nivolumab plus ipilimumab in advanced melanoma (early and randomized studies)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Combination anti-PD-1 (nivolumab) + anti-CTLA-4 (ipilimumab) induced rapid and deep tumor regressions with higher ORR and PFS than ipilimumab alone in cited trials; combinations are associated with significant immune-related toxicity (detailed rates not provided in this review).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Nivolumab plus ipilimumab in advanced melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_identifier</strong></td>
                            <td>Wolchok et al. 2013 / Postow et al. 2015 (combination trials)</td>
                        </tr>
                        <tr>
                            <td><strong>paper_title</strong></td>
                            <td>Nivolumab plus ipilimumab in advanced melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2013</td>
                        </tr>
                        <tr>
                            <td><strong>doi_or_trial_id</strong></td>
                            <td>10.1056/NEJMoa1302369</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>phase I/II and randomized studies (combination therapy)</td>
                        </tr>
                        <tr>
                            <td><strong>setting</strong></td>
                            <td>metastatic/unresectable, untreated and previously treated cohorts reported depending on trial</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>varied by trial (review cites e.g., 86 patients in an early cohort and 142 in an untreated randomized cohort; review aggregates results)</td>
                        </tr>
                        <tr>
                            <td><strong>therapy_regimen</strong></td>
                            <td>Nivolumab + ipilimumab combination (regimens/doses not specified in review)</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_monotherapy</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>duration_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>stopping_criteria</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>median_time_on_therapy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_at_discontinuation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_response_stratified_outcomes</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_by_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>compare_stop_vs_continue</strong></td>
                            <td>Trials compared combination vs ipilimumab monotherapy (improved ORR and PFS); not a stop-vs-continue duration comparison.</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_rate_after_stop</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>re_treatment_outcomes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_vs_duration</strong></td>
                            <td>Combination produced higher immune-related toxicity in trials cited; review does not link toxicity incidence to total duration on therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_guiding_stop</strong></td>
                            <td>No biomarker-based discontinuation approach discussed for combination therapy in review.</td>
                        </tr>
                        <tr>
                            <td><strong>cost_effectiveness</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_after_stop</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>authors_recommendation</strong></td>
                            <td>No specific guidance on duration or response-adapted stopping for combination regimens in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>key_limitations</strong></td>
                            <td>Review summarizes efficacy/toxicity but lacks any stopping-rule or duration strategy data for combination therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>country_or_registry</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>notes</strong></td>
                            <td>Cited to support rationale for combinations improving response depth, but stopping/duration questions remain unaddressed in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy', 'publication_date_yy_mm': '2015-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e81.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e81.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD-1 therapy duration strategies and outcomes in melanoma, including planned/actual duration, stopping rules, and whether optimal duration differs by depth of response (CR/PR/SD). Capture setting (metastatic vs adjuvant), regimen, response-stratified relapse and survival after stopping, comparisons of stopping vs continuing, biomarkers guiding discontinuation (e.g., PET/ctDNA), retreatment outcomes after relapse, toxicity with prolonged therapy, and any cost-effectiveness or modeling analyses. Prefer concise, numeric, and timepoint-specific results where available.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PD-L1 expression (IHC)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Programmed death-ligand 1 expression by tumor cells (immunohistochemistry)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Tumor PD-L1 expression is discussed as a potential predictive biomarker for clinical activity of anti-PD-1 therapy; the review notes correlation in some studies but also that many PD-L1+ tumors do not respond and some PD-L1- tumors do respond.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_identifier</strong></td>
                            <td>Taube et al. 2012 (biomarker study cited)</td>
                        </tr>
                        <tr>
                            <td><strong>paper_title</strong></td>
                            <td>Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2012</td>
                        </tr>
                        <tr>
                            <td><strong>doi_or_trial_id</strong></td>
                            <td>10.1126/scitranslmed.3003689</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>biomarker/observational pathology study (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>setting</strong></td>
                            <td>melanocytic lesions / melanoma (biopsy-based analysis)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapy_regimen</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_monotherapy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>duration_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>stopping_criteria</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>median_time_on_therapy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_at_discontinuation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_response_stratified_outcomes</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_by_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>compare_stop_vs_continue</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_rate_after_stop</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>re_treatment_outcomes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_vs_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_guiding_stop</strong></td>
                            <td>Review presents PD-L1 IHC as a potential predictor of response to anti-PD-1 therapy but does not report its use to guide treatment discontinuation or provide predictive performance metrics for stopping.</td>
                        </tr>
                        <tr>
                            <td><strong>cost_effectiveness</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_after_stop</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>authors_recommendation</strong></td>
                            <td>Review does not recommend using PD-L1 to guide discontinuation; suggests additional studies are needed.</td>
                        </tr>
                        <tr>
                            <td><strong>key_limitations</strong></td>
                            <td>PD-L1 is an imperfect predictor: many PD-L1+ tumors do not respond and some PD-L1- tumors do respond, per review.</td>
                        </tr>
                        <tr>
                            <td><strong>country_or_registry</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>notes</strong></td>
                            <td>PD-L1 discussed as predictive biomarker for response, not as a validated discontinuation marker in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy', 'publication_date_yy_mm': '2015-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. <em>(Rating: 2)</em></li>
                <li>A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. <em>(Rating: 2)</em></li>
                <li>Pembrolizumab versus ipilimumab in advanced melanoma. <em>(Rating: 2)</em></li>
                <li>Nivolumab in previously untreated melanoma without BRAF mutation. <em>(Rating: 2)</em></li>
                <li>Nivolumab plus ipilimumab in advanced melanoma. <em>(Rating: 2)</em></li>
                <li>Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. <em>(Rating: 1)</em></li>
                <li>Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>